Journal of Liver

Nucleic acid polymers: Broad spectrum antiviral agents and their development as the backbone of new antiviral therapies for the treatment of chronic HBV and HBV/HDV infection

3^rd World Congress on Hepatitis and Liver Diseases

October 10-12, 2016 Dubai, UAE

Andrew Vaillant

Replicor Inc., Canada

Keynote: J Liver

Abstract:

Nucleic acid polymers (NAPs) are an emerging antiviral technology with broad spectrum activity in a variety of enveloped viruses. Through a novel, sequence independent application of oligonucleotide technology, NAPs are able to interfere with entry and post entry mechanisms in many of the viral infections afflicting humans. The pharmacologic features of NAPs, the mechanistic basis for their broad spectrum antiviral activity and their unique antiviral properties in HBV and HDV infection will be discussed as well as their antiviral effects and ability to synergize with immunotherapy to achieve functional control of infection in completed and ongoing clinical trials in patients with chronic HBV infection and HBV/HDV co-infection.

Biography :

Andrew Vaillant is the inventor of Replicor’s NAP technology and has more than 15 years of experience in viral biology, antiviral drug development and nucleic acid chemistry. He has authored numerous publications and patents on the development and use of NAPs as agents to treat infectious diseases. He previously held positions at two biotechnology companies in Montreal. He was a Postdoctoral Fellow at the Montreal Neurological Institute and holds a PhD in Cell Biology from the University of Ottawa, Canada.

Email: availlant@replicor.com